1.
Oncoimmunology
; 5(1): e1064579, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26942081
RESUMO
Dendritic cell (DC) cancer vaccines have shown limited clinical benefit. Thus, the identification of signals and molecular pathways that potentiate the immunogenicity of DCs has become a major challenge in cancer research. Our studies demonstrate that triiodothyronine endows DCs with enhanced ability to stimulate cytotoxic T-cell responses with implications in DC-based immunotherapy.